The ICI therapy regimes were as follows: ipilimumab (3 mg/kg) every 3 weeks, nivolumab (3 mg/kg) every 2 weeks, pembrolizumab (2 mg/kg) every 3 weeks or combined ipilimumab (3 mg/kg) every 3 weeks and nivolumab (1 mg/kg) every 3 weeks....About 90% of all patients whose tumors harbored amplification of MDM2 (7 out of 8), MDM4 (8 out of 9) or EGFR (8 out of 9) developed PD and 66% of the patients with MDM4 amplification presented with HPD (6 out of 9)....Patients with amplification (≥4 copies) of MDM2, MDM4 or EGFR had no worse survival than patients without these amplifications (Figure S2).